Bruker Announces Five Ultra-High Field NMR Orders from Europe and Brazil
September 17 2015 - 6:01AM
Business Wire
Bruker (NASDAQ: BRKR) today announced five orders for ultra-high
field (UHF) nuclear magnetic resonance (NMR) spectroscopy systems
from Europe and Brazil in recent months. These UHF systems have
been funded for cutting-edge NMR research in structural biology,
intrinsically disordered proteins (IDPs), membrane proteins,
macro-molecular complexes and interactions, cell biology, disease
research, as well as in advanced materials research.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20150917005142/en/
Next generation Aeon 1.2 GHz NMR system
(Photo: Business Wire).
Bruker defines UHF as NMR systems with 1H proton frequency of
900 MHz or above. Other high-field 700, 800 and 850 MHz orders are
not included in the UHF definition. The recent UHF NMR orders
include three 900 and 950 MHz systems from Brazil, Switzerland and
the UK, with revenue typically within 18 months from order:
- The Federal University of Rio de Janeiro (UFRJ) in
Brazil is expanding its existing structural biology facility with
the addition of a 900 MHz NMR spectrometer. As one of the leading
universities in South America, the new 900 MHz system will be
available as a regional resource for research in protein structure
and dynamics, protein folding and structure of nucleic acids.
Professor Fabio C. L. Almeida of UFRJ commented: "Having a 900 MHz
will have a strong impact on the development of NMR and structural
biology in Brazil and Latin America. It will offer us advantages
and capabilities over other techniques in tackling important
biological and technological problems."
- The École Polytechnique Féderale de Lausanne (EPFL) in
Switzerland has ordered a Bruker 900 MHz instrument with the
highest field wide-bore (89 mm inner diameter) magnet currently
available for solid-state NMR. It will enable EPFL researchers to
tackle problems in complex systems such as enzymes, catalytic
nanoparticles, active pharmaceutical ingredients and live model
organisms.
- The University of Leeds in the UK is expanding its
Astbury Centre for Structural Molecular Biology with a 950 MHz NMR
equipped with a novel CryoProbe that is now designed for
both 13C and 15N direct detection, besides traditional 1H indirect
detection. This technology makes the instrument suitable for
determining structures, dynamics and interactions of globular
proteins, as well as for advanced functional and disease mechanism
studies of intrinsically disordered proteins (IDPs). Professor Alex
Breeze at the University of Leeds stated: “We are tremendously
excited to be installing our new 950 MHz instrument, which will
complement our investment in cutting-edge cryo-electron microscopy
and other structural techniques. In particular, the combination of
950 MHz field strength and the novel direct-detection and
low-volume capabilities of the latest CryoProbes will allow
us to access critical structural and dynamic information on
important biological systems and medically relevant targets with
the optimum sensitivity and resolution.”
In 2015, Bruker also has received two additional orders for
next-generation GHz-class systems from France and Germany, and
Bruker’s backlog for GHz-class NMR systems has now increased to
nine (9) systems for different European and Canadian customers.
Bruker expects to begin to recognize revenues from next-generation
Aeon™ 1.0 GHz systems in 2016. The Aeon 1.2
GHz systems backlog is projected to ship over several years,
starting in late 2017 or 2018. Revenue timing for future 1.2
GHz systems has inherent risks, and depends on further progress
in high-temperature superconductor (HTS) materials and HTS-based
NMR magnet technology.
- A 1.2 GHz instrument ordered by the CNRS is expected to be
placed at the University of Lille in France and will be
available to the French and European scientific community through
the NMR Large Scale Facility, hosted by the Centre National de la
Recherche Scientifique (CNRS). Dr. Jean-Pierre Simorre, Director of
the Large Scale Facility, explained: “The acquisition of this 1.2
GHz spectrometer will keep France at the leading edge of NMR
technology. This national instrument will be installed in Lille for
a broad panel of interdisciplinary research areas ranging from
structural biology to catalysis, from sustainable energy
development to bio-medical applications.”
- The Center for Biomolecular Magnetic Resonance (BMRZ) at the
Goethe University in Frankfurt, Germany is part of the
European Large Scale Facilities and incorporates various high-field
liquid and solid-state NMR spectrometers, as well as DNP-NMR and
EPR instrumentation. The 1.2 GHz NMR ordered recently is expected
to be available to the scientific community in Germany and Europe.
Research at the BMRZ is dedicated to the elucidation of structure
and functional mechanisms of biomolecules ranging from RNA and
RNA-protein complexes, via large protein complexes to membrane
proteins. Professor Harald Schwalbe from the BMRZ remarked: "We are
very happy to have placed the order for the next generation of NMR.
The 1.2 GHz NMR system will allow us to investigate structure,
dynamics and biological function of increasingly large and
challenging biomolecular complexes. We will also be able to provide
access for European researchers."
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may be identified by the use of
words such as “anticipate,” “believe,” “expect,” “will,” “may,”
“estimate,” “plan,” “outlook,” and “project” and other similar
expressions that predict or indicate future events or trends or
that are not statements of historical matters. Such forward-looking
statements reflect the views of management at the time such
statements are made and are subject to a number of risks,
uncertainties, estimates, and assumptions that may cause actual
results to differ materially from current expectations. These
statements include our expectations related to the production and
delivery of technologically advanced UHF NMR systems and the amount
and timing of future revenues from UHF NMR systems orders currently
in our backlog. Although we believe the assumptions upon which
these forward-looking statements are based are reasonable, any of
these assumptions could prove to be inaccurate and the
forward-looking statements based on these assumptions could be
incorrect. Our actual future performance may differ materially from
such expectations as a result of important risk factors, which
include, in addition to those identified in the our Annual Report
on Form 10-K for the year ended December 31, 2014 and our other
subsequent filings with the Securities and Exchange Commission,
risks and uncertainties associated with our ability to develop
high-temperature superconductor (HTS) materials and HTS-based
magnets required for 1.2 GHz NMR systems. These risks and
uncertainties could cause actual results to differ materially from
those stated or implied in these forward-looking statements. We
expressly disclaim any obligation to update or revise these
forward-looking statements, except as required by law or
regulation.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker’s high-performance scientific
research instruments and high-value analytical solutions enable
scientists to explore life and materials at molecular, cellular and
microscopic levels.
In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science
molecular research, in applied and pharma applications, in
microscopy, nano-analysis and industrial applications, as well as
in cell biology, preclinical imaging, clinical research,
microbiology and molecular diagnostics. For more information,
please visit www.bruker.com.
For more information on Bruker, please visit www.bruker.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150917005142/en/
Bruker CorporationMedia Contact:Dr. Thorsten Thiel, +49
(721) 5161–6500Director of Marketing
Communicationsthorsten.thiel@bruker.comorInvestor
Contact:Joshua Young, +1-978-663-3660, ext. 1479VP, Investor
Relations & Corporate Developmentjoshua.young@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024